Vigabatrin

Neurotherapeutics

Volumn 4, Issue 1, 2007, Pages 163-172

  Wheless, James W ^a   Ramsay, R Eugene ^b   Collins, Stephen D ^c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c LUNDBECK RESEARCH USA   (United States)

Author keywords

complex partial seizures; epilepsy; infantile spasms; refractory epilepsy; vigabatrin; visual fields; West syndrome

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CARBAMAZEPINE; CORTICOSTEROID; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PLACEBO; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADD ON THERAPY; AGITATION; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; COLOR VISION; COMPLEX PARTIAL SEIZURE; CORRELATION ANALYSIS; DECISION MAKING; DEPRESSION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; EPIRETINAL MEMBRANE; HUMAN; INCIDENCE; INFANTILE SPASM; IRRITABILITY; LABORATORY TEST; MONOTHERAPY; PHYSICIAN; PIGMENT DISORDER; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RETINA DISEASE; RETINAL ARTERY NARROWING; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VISUAL FIELD DEFECT; WEIGHT GAIN;

ANIMALS; ANTICONVULSANTS; BRAIN; CLINICAL TRIALS; EPILEPSY; HUMANS; RISK ASSESSMENT; VIGABATRIN; VISION DISORDERS; VISUAL FIELDS;

EID: 33846264986     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2006.11.008     Document Type: Article

References (134)

1. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 3 (2004) 618-621
2. Berg A.T., Shinnar S., Levy S.R., and Testa F.M. Newly diagnosed epilepsy in children: presentation at diagnosis. Epilepsia 40 (1999) 445-452
3. Forsgren L., Bucht G., Eriksson S., and Bergmark L. Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study. Epilepsia 37 (1996) 224-229
4. Murro AM. Complex partial seizures [Internet]. Updated: December 5, 2005. Accessed July 5, 2006. Available at: http://www.emedicine.com/NEURO/topic74.htm.
5. Elterman R.D., Shields W.D., Mansfield K.A., Nakagawa J., and US Infantile Spasms Vigabatrin Study Group. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 57 (2001) 1416-1421
6. Mackay M.T., Weiss S.K., Adams-Webber T., et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 62 (2004) 1668-1681
7. Nabbout R. A risk-benefit assessment of treatments for infantile spasms. Drug Saf 24 (2001) 813-828
8. Glauser T.A. Following catastrophic epilepsy patients from childhood to adulthood. Epilepsia 45 suppl 5 (2004) 23-26
9. Riikonen R. Long-term outcome of patients with West syndrome. Brain Dev 23 (2001) 683-687
10. Product Information: Sabril, vigabatrin. Aventis Pharma Inc., Laval, Quebec, Canada.
11. Guberman A. Vigabatrin. Can J Neurol Sci 23 4 (1996) S13-S17
12. Rey E., Pons G., Richard M.O., et al. Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children. Br J Clin Pharmacol 30 (1990) 253-257
13. Rimmer E.M., and Richens A. Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol 27 suppl 1 (1989) 27S-33S
14. Gatti G., Bartoli A., Marchiselli R., et al. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. Br J Clin Pharmacol 36 (1993) 603-606
15. Patsalos P.N., and Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2 (2003) 347-356
16. Garaizar C., Martinez-González M.J., Fernández-Cuesta M.A., et al. Seguimiento a Largo Plazo de la Epilepsia Infantil Tratada con vigabatrina, Fuere de los Ensayos Clinicos [Long-term follow-up of childhood epilepsy treated with vigabatrin outside of clinical trials. [In Spanish]. Rev Neurol 29 (1999) 201-207
17. Chiron C., Dumas C., Jambaque I., Mumford J., and Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 26 (1997) 389-395
18. Satishchandra P., Kashyap B., Goverdhan S., et al. Vigabatrin in intractable complex partial epilepsy. Epilepsia 40 suppl 2 (1999) 256 Abstract
19. Data on file. Ovation Pharmaceuticals. Protocol 71754-3-C-025.
20. Data on file. Ovation Pharmaceuticals. Protocol 71754 3 C 024.
21. Cramer J.A., Fisher R., Ben-Menachem E., French J., and Mattson R.H. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 40 (1999) 590-600
22. Coppola G. Treatment of partial seizures in childhood: an overview. CNS Drugs 18 (2004) 133-156
23. Luna D., Dulac O., Pajot N., and Beaumont D. Vigabatrin in the treatment of childhood epilepsies: a single-blind placebo-controlled study. Epilepsia 30 (1989) 430-437
24. Dalla Bernardina B., Fontana E., Vigevano F., et al. Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single-blind dose-increasing study. Epilepsia 36 (1995) 687-691
25. Gobbi G., Pini A., Bertani G., et al. Prospective study of first-line vigabatrin monotherapy in childhood partial epilepsies. Epilepsy Res 35 (1999) 29-37
26. Zamponi N., and Cardinali C. Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. Arch Neurol 56 (1999) 605-607
27. Appleton R.E., Peters A.C., Mumford J.P., and Shaw D.E. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 40 (1999) 1627-1633
28. Chiron C., Dulac O., Beaumont D., Palacios L., Pajot N., and Mumford J. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol suppl 2 (1991) S52-S59
29. Aicardi J., Mumford J.P., Dumas C., Wood S., and Sabril IS Investigator and Peer Review Groups. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Epilepsia 37 (1996) 638-642
30. Mitchell W.G., and Shah N.S. Vigabatrin for infantile spasms. Pediatr Neurol 27 (2002) 161-164
31. Vigevano F., and Cilio M.R. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia 38 (1997) 1270-1274
32. Lux A.L., Edwards S.W., Hancock E., et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol 4 (2005) 712-717
33. Data on file. Ovation Pharmaceuticals. IND 47,707/Protocol 1A.
34. Elterman R.D., Collins S.D., Shields W.D., Mansfield K.A., and Nakagawa J. Efficacy of vigabatrin in subjects with infantile spasms. Epilepsia 46 suppl 8 (2005) 167 Abstract
35. Appleton R.E. Guideline may help in prescribing vigabatrin. BMJ 317 (1998) 1322 Letter
36. Frisen L., and Malmgren K. Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 81 (2003) 466-473
37. Lux A.L., Edwards S.W., Osborne J.P., et al. Revised guideline for prescribing vigabatrin in children: guideline's claim about infantile spasms is not based on appropriate evidence. BMJ 322 (2001) 236-237 Letter
38. Vigabatrin Paediatric Advisory Group. Guideline for prescribing vigabatrin in children has been revised. BMJ 320 (2000) 1404-1405
39. Riikonen R. ACTH therapy of West syndrome: Finnish views. Brain Dev 23 (2001) 642-646
40. Paul S.R., Krauss G.L., Miller N.R., Medura M.T., Miller T.A., and Johnson M.A. Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making. Epilepsia 42 (2001) 525-530
41. Wheless J.W., Clarke D.F., and Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 20 suppl 1 (2005) S1-S56
42. Spence S.J., and Sankar R. Visual field defects and other ophthalmological disturbances associated with vigabatrin. Drug Saf 24 (2001) 385-404
43. Guberman A., Bruni J., and The Canadian Vigabatrin Study Group. Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. Seizure 9 (2000) 112-118
44. Jambaque I., Chiron C., Dumas C., Mumford J., and Dulac O. Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. Epilepsy Res 38 (2000) 151-160
45. Sander J.W., Hart Y.M., Trimble M.R., and Shorvon S.D. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 54 (1991) 435-439
46. Aldenkamp A.P., Vermeulen J., Mulder O.G., et al. Gamma-vinyl GABA (vigabatrin) and mood disturbances. Epilepsia 35 (1994) 999-1004
47. Wong I.C. Retrospective study of vigabatrin and psychiatric behavioural disturbances. Epilepsy Res 21 (1995) 227-230
48. Thomas L., Trimble M., Schmitz B., and Ring H. Vigabatrin and behaviour disorders: a retrospective survey. Epilepsy Res 25 (1996) 21-27
49. Kälviäinen R., Nousianen I., Mäntyjärvi M., et al. Initial vigabatrin monotherapy is associated with increased risk of visual field constriction: a comparative follow-up study with patients on initial carbamazepine monotherapy and healthy controls. Epilepsia 39 suppl 6 (1998) 72 Abstract
50. Koehler J., Thömke F., Tettenborn B., et al. Influence of new antiepileptic drugs on visual evoked potentials. Epilepsia 40 suppl 2 (1999) 288 Abstract
51. Sankar R., and Wasterlain C.G. Is the devil we know the lesser of two evils?. Vigabatrin and visual fields. Neurology 52 (1999) 1537-1538 Comment
52. Vanhatalo S., Paakkonen L., and Nousiainen I. Visual field constriction in children treated with vigabatrin. Neurology 52 (1999) 1713-1714
53. Iannetti P., Spalice A., Perla F.M., Conicella E., Raucci U., and Bizzarri B. Visual field constriction in children with epilepsy on vigabatrin treatment. Pediatrics 106 (2000) 838-842
54. Krauss G.L., Johnson M.A., and Miller N.R. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 50 (1998) 614-618
55. Miller N.R., Johnson M.A., Paul S.R., et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 53 (1999) 2082-2087
56. Choi H.J., and Kim D.M. Visual field constriction associated with vigabatrin: retinal nerve fiber layer photographic correlation. J Neurol Neurosurg Psychiatry 75 (2004) 1395
57. Wild J.M., Martinez C., Reinshagen G., and Harding G.F. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40 (1999) 1784-1794
58. Lawden M.C., Eke T., Degg C., Harding G.F., and Wild J.M. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 67 (1999) 716-722
59. Gross-Tsur V., Banin E., Shahar E., Shalev R.S., and Lahat E. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol 48 (2000) 60-64
60. Lawden M.C., Eke T., Degg C., et al. Visual field defects associated with vigabatrin treatment. Epilepsia 40 suppl 2 (1999) 256 Abstract
61. DeToledo J.C., Westall C.A., and Collins S.D. Vigabatrin induced visual fields defects: Update 2006. American Epilepsy Society Annual Meeting, December 1-5 (2006) Abstract 585 (poster)
62. Eke T., Talbot J.F., and Lawden M.C. Severe persistent visual field constriction associated with vigabatrin. BMJ 314 (1997) 180-181
63. Wong I.C., Mawer G.E., and Sander J.W. Severe persistent visual field constriction associated with vigabatrin: reaction might be dose dependent. BMJ 314 (1997) 1693-1694 Comment
64. Daneshvar H., Racette L., Coupland S.G., Kertes P.J., Guberman A., and Zackon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 106 (1999) 1792-1798
65. Buncic J.R., Westall C.A., Panton C.M., Munn J.R., MacKeen L.D., and Logan W.J. Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 111 (2004) 1935-1942
66. Wild J.M., Hope-Ross M., Harding G.F.A., and Betts T.A. Vigabatrin retinopathy. Invest Ophthalmol Vis Sci 43 (2002) E-abstract 238
67. Pelosse B., Momtchilova M., Roubergue A., Doummar D., Billette de Villemeur T., and Laroche L. [Study of visual field and vigabatrin treatment in children]. In French. J Fr Ophtalmol 24 (2001) 1075-1080
68. Harding G.F., Robertson K., Spencer E.L., and Holliday I. Vigabatrin: its effect on the electrophysiology of vision. Doc Ophthalmol 104 (2002) 213-229
69. Harding G.F.A., Wild J.M., Robertson K., et al. Electroculography, ERGs, multifocal ERGs and VEPs in epileptic patients showing visual field disorder. Electroencephalogr Clin Neurophysiol 103 (1997) 96 Abstract.
70. McDonagh J., Stephen L.J., Dolan F.M., et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 61 (2003) 1690-1694
71. Morong S., Westall C.A., Nobile R., et al. Longitudinal changes in photopic OPs occurring with vigabatrin treatment. Doc Ophthalmol 107 (2003) 289-297
72. Morong S.E., Westall C.A., Buncic R.J., Snead O.C., Logan W.J., and Weiss S. Sweep visual evoked potentials in infants with infantile spasms before and during vigabatrin treatment. Invest Ophthalmol Vis Sci 43 (2003) E-abstract 2720
73. Westall C.A., Logan W.J., Smith K., Buncic J.R., Panton C.M., and Abdolell M. The Hospital for Sick Children, Toronto, longitudinal ERG study of children on vigabatrin. Doc Ophthalmol 104 (2002) 133-149
74. Harding G.F., Wild J.M., Robertson K.A., et al. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. Epilepsia 41 (2000) 1420-1431
75. Harding G.F., Spencer E.L., Wild J.M., Conway M., and Bohn R.L. Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children. Neurology 58 (2002) 1261-1265
76. Ruether K., Pung T., Kellner U., Schmitz B., Hartmann C., and Seeliger M. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol 116 (1998) 817-819
77. Hardus P., Verduin W.M., Postma G., Stilma J.S., Berendschot T.T., and van Veelen C.W. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia 41 (2000) 581-587
78. Hardus P., Verduin W.M., Postma G., Stilma J.S., Berendschot T.T., and van Veelen C.W. Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin. Br J Ophthalmol 84 (2000) 788-790
79. Gonzalez P.A., McCall A., McQuistan A., Keating D., Brodie M.J., and Parks S. Assessing retinal toxicity of vigabatrin and other GABA-ergic drugs in patients with epilepsy. Association for Research in Vision and Ophthalmology 46 (2005) 1658 :B521.
80. Gonzalez P.A., Parks S., Kelly K., and Brodie M.J. Progression of neuro-retinal toxicity in patients on vigabatrin: objective assessment using the wide field multifocal electroretinogram. Epilepsia 45 suppl 7 (2004) 188 Abstract
81. Nousiainen I., Kälviäinen R., and Mäntyjärvi M. Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers. Br J Ophthalmol 84 (2000) 622-625
82. Nousiainen I., Kälviäinen R., and Mäntyjärvi M. Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy. Ophthalmology 107 (2000) 884-888
83. Bayer A., Thiel H.J., Zrenner E., Paulus W., Ried S., and Schmidt D. [Sensitive physiologic perceptual tests for ocular side effects of drugs exemplified by various anticonvulsants]. In German. Ophthalmologe 92 (1995) 182-190
84. Manuchehri K., Goodman S., Siviter L., and Nightingale S. A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 84 (2000) 499-505
85. Besch D., Safran A.B., Kurtenbach A., et al. Visual field defects and inner retinal dysfunction associated with vigabatrin. Invest Ophthalmol Vis Sci 41 (2000) 892S Abstract 55.
86. Johnson M.A., Krauss G.L., Miller N.R., Medura M., and Paul S.R. Visual function loss from vigabatrin: effect of stopping the drug. Neurology 55 (2000) 40-45
87. Kälviäinen R., Nousiainen I., Mäntyjärvi M., et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 53 (1999) 922-926
88. Kälviäinen R., Nousiainen I., Mäntyjärvi M., et al. Prevalence of concentric visual field constriction in adult epilepsy patients with vigabatrin treatment. Neurology 52 suppl 2 (1999) A235-A236 Abstract
89. Gonzalez P, McCall A, McQuistan A, Keating D, Kelly K, Brodie MJ, Parks S. The assessment of neuro-retinal toxicity in patients with epilepsy on vigabatrin. Presented at: 42nd Annual Symposium, International Society of Clinical Electrophysiology in Vision, Glasgow, Scotland. August 22-26, 2005 (poster).
90. Wilson E.A., and Brodie M.J. Severe persistent visual field constriction associated with vigabatrin: chronic refractory epilepsy may have role in causing these unusual lesions. BMJ 314 (1997) 1693 Comment
91. Wohlrab G., Boltshauser E., Schmitt B., Schriever S., and Landau K. Visual field constriction is not limited to children treated with vigabatrin. Neuropediatrics 30 (1999) 130-132
92. Arndt C.F., Derambure P., Defoort-Dhellemmes S., and Hache J.C. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 52 (1999) 1201-1205
93. Arndt C.F., Derambure P., Defoort S., et al. Is visual impairment related to vigabatrin reversible?. Epilepsia 40 suppl 2 (1999) 256 Abstract
94. Llerda M.J., Lasaosa S.S., Juste T.C., et al. Visual field defects associated with vigabatrin therapy: prevalence, characteristics and follow-up. Epilepsia 41 suppl 7 (2000) 240 Abstract
95. Toggweiler S., and Wieser H.G. Concentric visual field restriction under vigabatrin therapy: extent depends on the duration of drug intake. Seizure 10 (2001) 420-423
96. Specchio L.M., Bellizzi M., La Neve A., et al. Visual impairment in adult epileptic patients treated with vigabatrin. Neurology 54 suppl 3 (2000) A308 Abstract
97. Jensen H., Sjo O., Uldall P., and Gram L. Vigabatrin and retinal changes. Doc Ophthalmol 104 (2002) 171-180
98. Rintahaka P., Granström M.L., Lappi M., et al. Visual field defects in vigabatrin-treated children with epilepsy. Epilepsia 41 suppl 7 (2000) 196-197 Abstract
99. Ascaso F.J., Lopez M.J., Mauri J.A., and Cristobal J.A. Visual field defects in pediatric patients on vigabatrin monotherapy. Doc Ophthalmol 107 (2003) 127-130
100. Westall C.A., Nobile R., Morong S., Buncic J.R., Logan W.J., and Panton C.M. Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Doc Ophthalmol 107 (2003) 299-309
101. Westall C.A., Nobile R., Buncic J.R., and Abdolell M. Electroretinogram indicators of toxicity in children taking the anti epileptic medication vigabatrin. Invest Ophthalmol Vis Sci 46 (2005) E-Abstract 612
102. Westall C. Visual electrophysiology to detect drug induced ocular toxicity: are abnormal results suggestive of toxicity? Presented at: 42nd Annual Symposium, International Society for Clinical Electrophysiology of Vision, Glasgow, Scotland, August 22-26, 2005 (oral presentation).
103. Westall C.A., Nobile R., and Buncic J.R. Which factors contribute to worsening of ERGs in children taking the anti-epileptic drug vigabatrin?. Invest Ophthalmol Vis Sci 45 (2006) E-Abstract 775
104. Hammoudi D.S., Lee S.S.F., Madison A., et al. Reduced visual function associated with infantile spasms in children on vigabatrin therapy. Invest Ophthalmol Vis Sci 46 (2005) 514-520
105. Predictor variable analysis to determine onset of retinal toxicity in children on vigabatrin therapy. Invest Ophthalmol Vis Sci 46 (2005) E-Abstract 611
106. Kälviäinen R., and Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 15 (2001) 217-230
107. Committee for Proprietary Medicinal Products (CPMP), European Agency for the Evaluation of Medicinal Products (EMeA). Opinion following an article 12 referral: Vigabatrin. Report no. CPMP/1357/99. November 5, 1999. Available at: http://www.emea.europa.eu/pdfs/human/phv/135799ENB.pdf.
108. Hardus P., Verduin W.M., Berendschot T.T., et al. The value of electrophysiology results in patients with epilepsy and vigabatrin associated visual field loss. Acta Ophthalmol Scand 79 (2001) 169-174
109. Hardus P., Verduin W.M., Engelsman M., et al. Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia 42 (2001) 262-267
110. Benozzi J.I., Jaliffa C., Nahum P., et al. Visual alterations in Argentinean patients receiving vigabatrin. Invest Ophthalmol Vis Sci 42 4 (2001) S65 Abstract
111. Newman W.D., Tocher K., and Acheson J.F. Vigabatrin associated visual field loss: risk factors and natural history. Invest Ophthalmol Vis Sci 42 4 (2001) S937 Abstract
112. Kinirons P., Cavalleri G.L., O'Rourke D., et al. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia 47 (2006) 311-317
113. Vanhatalo S., Nousiainen I., Eriksson K., et al. Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia 43 (2002) 748-756
114. Malmgren K., Ben-Menachem E., and Frisen L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 42 (2001) 609-615
115. Schmidt T., Ruther K., Jokiel B., Pfeiffer S., Tiel-Wilck K., and Schmitz B. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?. J Neurol 249 (2002) 1066-1071
116. Steinhoff B.J., Freudenthaler N., and Paulus W. The influence of established and new antiepileptic drugs on visual perception. 1. A placebo-controlled, double-blind, single-dose study in healthy volunteers. Epilepsy Res 29 (1997) 35-47
117. Tiel-Wilck K., Jokiel B., Zinser P., et al. Afferent visual function after single dose application of gamma-vinyl-GABA. Neuroophthalmology 15 (1995) 305-310 Abstract
118. Best J.L., and Acheson J.F. The natural history of vigabatrin associated visual field defects in patients electing to continue their medication. Eye 19 (2004) 41-44
119. Newman W.D., Tocher K., and Acheson J.F. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 16 (2002) 567-571
120. Mauguiere F., Chauvel P., Dewailly J., Dousse N., and PMS Study Multicenter Group. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. Epilepsia 38 (1997) 301-308
121. American Academy of Ophthalmology. Automated perimetry. Ophthalmology 103 (1996) 1144-1151
122. Westall C.A., Panton C.M., and Levin A.V. Time courses for maturation of electroretinogram responses from infancy to adulthood. Doc Ophthalmol 96 (1998) 355-379
123. National Institutes of Health Consensus Conference. Surgery for epilepsy. JAMA 264 (1990) 729-733
124. Brodie M.J., and Kwan P. Staged approach to epilepsy management. Neurology 58 8 suppl 5 (2002) S2-S8
125. Meador K.J. Cognitive outcomes and predictive factors in epilepsy. Neurology 58 8 suppl 5 (2002) S21-S26
126. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45 (2004) 410-423 [Erratum in: Epilepsia 2004;45:1299]
127. Tomson T., Walczak T., Sillanpaa M., and Sander J.W. Sudden unexpected death in epilepsy: a review of incidence and risk factors. Epilepsia 46 suppl 11 (2005) 54-61
128. Mayer H., Benninger F., Urak L., Plattner B., Geldner J., and Feucht M. EKG abnormalities in children and adolescents with symptomatic temporal lobe epilepsy. Neurology 63 (2004) 324-328
129. Kivity S., Lerman P., Ariel R., Danziger Y., Mimouni M., and Shinnar S. Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia 45 (2004) 255-262
130. Guerrini R., and Parmeggiani L. Practitioner review: use of antiepileptic drugs in children. J Child Psychol Psychiatry 47 (2006) 115-126
131. Mackay M., Weiss S., and Snead III O.C. Treatment of infantile spasms: an evidence-based approach. Int Rev Neurobiol 49 (2002) 157-184
132. Van Ness P.C. Therapy for the epilepsies. Arch Neurol 59 (2002) 732-735
133. Devinsky O. Patients with refractory seizures. N Engl J Med 340 (1999) 1565-1570
134. Shields W.D. Infantile spasms: little seizures, big consequences. Epilepsy Curr 6 (2006) 63-69